PTC Therapeutics Posts $51.7 Million Q3 Loss but Beats Revenue and Earnings Estimates

PTC Therapeutics Inc. (PTCT) reported a loss of $51.7 million, or 62 cents per share, in its third quarter, while adjusted earnings of 61 cents per share beat Wall Street's estimate of 17 cents, according to Zacks Investment Research. Revenue for the period reached $357.8 million, exceeding the $311.1 million forecast by three Zacks analysts. The Warren, New Jersey-based biopharmaceutical company expects full-year revenue between $1.29 billion and $1.32 billion. The quarterly results, released Thursday, surpassed analyst expectations on both earnings and revenue.